Bristol Myers Squibb (BMY) Cash & Current Investments (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Cash & Current Investments for 18 consecutive years, with $11.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Current Investments fell 18.64% year-over-year to $11.1 billion in Q2 2026; TTM through Jun 2026 was $11.1 billion, a 18.64% decrease from a year earlier, with the FY2025 full-year figure at $10.7 billion, down 1.71% from the prior year.
• Cash & Current Investments was $11.1 billion for Q2 2026 at Bristol Myers Squibb, up from $10.5 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $16.5 billion in Q3 2025 and troughed at $6.7 billion in Q2 2024.
• A 5-year average of $10.8 billion and a median of $10.6 billion in 2025 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments tumbled 45.46% in 2022 and jumped 104.46% in 2025, its largest moves.
• Over 5 years, Cash & Current Investments stood at $9.3 billion in 2022, then jumped by 32.71% to $12.3 billion in 2023, then decreased by 11.57% to $10.9 billion in 2024, then dropped by 1.71% to $10.7 billion in 2025, then increased by 3.69% to $11.1 billion in 2026.
• The last three Cash & Current Investments figures came in at $11.1 billion (Q2 2026), $10.5 billion (Q1 2026), and $10.7 billion (Q4 2025), per Business Quant data.